Pear Therapeutics, Inc.

Equities

PEARQ

US7047231052

Biotechnology & Medical Research

Market Closed - OTC Markets 10:03:36 2024-03-22 am EDT 5-day change 1st Jan Change
0.000001 USD -99.00% Intraday chart for Pear Therapeutics, Inc. 0.00% 0.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. CI
Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. CI
Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc. CI
Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc. CI
First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc. CI
First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc. CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc. CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc. CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc. CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc. CI
Notice of Auction Resluts Filed by Pear Therapeutics, Inc. CI
Bidding Procedure Approved for Pear Therapeutics, Inc. CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from S&P TMI Index CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from NASDAQ Composite Index CI
Wall Street Set to Open Lower, March Retail Sales Fall More Than Expected MT
US Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment Reports MT
Top Premarket Decliners MT
Motion for Joint Administration Approved for Pear Therapeutics, Inc. CI
Top Midday Decliners MT
Pear Therapeutics Intends to Pursue a Sale of the Business or Assets CI
Pear Therapeutics, Inc. Announces Executive Changes CI
Pear Therapeutics, Inc. Announces Resignation of Corey Mccann, M.D., Ph.D. as Chief Executive Officer CI
Motion for Joint Administration Filed by Pear Therapeutics, Inc. CI
Motion for Asset Sale Filed by Pear Therapeutics, Inc. CI
Pear Therapeutics, Inc. Filed for Bankruptcy CI
Chart Pear Therapeutics, Inc.
More charts
Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
  1. Stock
  2. Equities
  3. Stock Pear Therapeutics, Inc. - OTC Markets
  4. News Pear Therapeutics, Inc.
  5. BTIG Adjusts Price Target for Pear Therapeutics to $5 From $11, Maintains Buy Rating